Product Information
Registration Status: ActiveSIN10847P
LOMFLOX TABLET 400mg is approved to be sold in Singapore with effective from 1999-03-31. It is marketed by ZYFAS MEDICAL CO, with the registration number of SIN10847P.
This product contains Lomefloxacin 400mg in the form of TABLET, FILM-COATED. It is approved for ORAL use.
This product is manufactured by IPCA LABORATORIES LTD in INDIA.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery.
Indication
For the treatment of bacterial infections of the respiratory tract (chronic bronchitis) and urinary tract, and as a pre-operative prophylactic to prevent urinary tract infection caused by: S.pneumoniae, H.influenzae, S.aureus, P.aeruginosa, E. cloacae, P. mirabilis, C. civersus, S. asprphyticus, E.coli, and K.pneumoniae.
Mechanism of Action
Lomefloxacin is a bactericidal fluoroquinolone agent with activity against a wide range of gram-negative and gram-positive organisms. The bactericidal action of lomefloxacin results from interference with the activity of the bacterial enzymes DNA gyrase and topoisomerase IV, which are needed for the transcription and replication of bacterial DNA. DNA gyrase appears to be the primary quinolone target for gram-negative bacteria. Topoisomerase IV appears to be the preferential target in gram-positive organisms. Interference with these two topoisomerases results in strand breakage of the bacterial chromosome, supercoiling, and resealing. As a result DNA replication and transcription is inhibited.
Pharmacokinetics
- Absorption
- Rapid and nearly complete with approximately 95% to 98% of a single oral dose being absorbed.
- Distribution
- Metabolism
- Minimally metabolized although 5 metabolites have been identified in human urine. 65% appears as the parent drug in urine and 9% as the glucuronide metabolite.
- Elimination
Clearance
* 271 mL/min/1.73 m2 [creatinine clearance of 110 mL/min/1.73 m2] * 31 mL/min/1.73 m2 [creatinine clearance of 0 mL/min/1.73 m2]
Toxicity
Adverse reactions include peripheral neuropathy, nervousness, agitation, anxiety, and phototoxic events (rash, itching, burning) due to sunlight exposure.
Active Ingredient/Synonyms
(+-)-1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid | 1,4-Dihydro-6,8-difluoro-1-ethyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid | LFLX | Lomefloxacine | Lomefloxacino | Lomefloxacinum | Lomefloxacin |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.